Inspire Medical Systems (INSP)

• Market cap: $4.71B
• 1 day: -0.97%
• 5 days: 4.36%
• 1 month: -0.57%
• 3 months: -18.67%
• 6 months: -19.42%
• Year to date: -16.29%
• 1 year: -34.46%
• 5 years: 121.02%
• 10 years: 534.03%
• Sector: Healthcare
• Industry: Medical Devices

About: Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

Employees: 1,246

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

39% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 44

33% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 8 (+2) [Q4]

4% more funds holding

Funds holding: 341 [Q3] → 353 (+12) [Q4]

0.64% more ownership

Funds ownership: 110.78% [Q3] → 111.43% (+0.64%) [Q4]

7% less repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 125

11% less capital invested

Capital invested by funds: $6.97B [Q3] → $6.2B (-$769M) [Q4]

26% less call options, than puts

Call options by funds: $54.8M | Put options by funds: $73.8M

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $175 10% upside
• Avg. target: $217 37% upside
• High target: $248 57% upside

8 analyst ratings

• positive: 6 75%
• neutral: 2 25%
• negative: 0 0%

Stifel Jonathan Block 10% 1-year accuracy 2 / 20 met price target	10% upside $175	Hold Maintained	21 Apr 2025
Keybanc Tim Rezvan 43% 1-year accuracy 19 / 44 met price target	36% upside $216	Overweight Maintained	21 Apr 2025
RBC Capital Shagun Singh 49% 1-year accuracy 33 / 68 met price target	36% upside $215	Outperform Maintained	15 Apr 2025
Truist Securities Richard Newitter 57% 1-year accuracy 29 / 51 met price target	48% upside $235	Buy Maintained	11 Feb 2025
Baird Mike Polark 67% 1-year accuracy 8 / 12 met price target	57% upside $248	Outperform Maintained	11 Feb 2025